CMG Pharmaceutical (058820) Fundamentals 2026 — Revenue Analysis | SniperIQ
CMG Pharmaceutical (058820) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩116.1B, trading at ₩785.00 on the KOE. This SniperIQ fundamentals page covers CMG Pharmaceutical's valuation, profitability (net margin -6.6%), revenue (₩105.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CMG Pharmaceutical's market cap?
CMG Pharmaceutical (058820) has a market capitalization of approximately ₩116.1B, trading at ₩785.00 on the KOE. Market cap moves with the live share price.
What is CMG Pharmaceutical's P/E ratio?
CMG Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is CMG Pharmaceutical?
CMG Pharmaceutical runs a net profit margin of -6.6%, a gross margin of 56.2%, and an operating margin of -4.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does CMG Pharmaceutical generate?
CMG Pharmaceutical reported revenue of ₩105.2B for fiscal year 2025, with net income of -₩9.0B and earnings per share (EPS) of -60.63. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does CMG Pharmaceutical pay a dividend?
CMG Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is CMG Pharmaceutical financially healthy?
CMG Pharmaceutical carries a debt-to-equity ratio of 0.44x and a current ratio of 1.25x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CMG Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CMG Pharmaceutical (058820) the key facts are: market cap ₩116.1B, revenue ₩105.2B, 52-week range 780-2205. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track CMG Pharmaceutical's full fundamentals live
Get CMG Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.